Abstract:The early growth response 1 (EGR-1) gene product is a transcription factor with role in differentiation and growth. We have previously shown that expression of exogenous EGR-1 in various human tumor cells unexpectedly and markedly reduces growth and tumorigenicity and, conversely, that suppression of endogenous Egr-1 expression by antisense RNA eliminates protein expression, enhances growth, and promotes phenotypic transformation. However, the mechanism of these effects remained unknown. The promoter of human transforming growth factor beta 1 (TGF-beta 1) contains two GC-rich EGR-1 binding sites. We show that expression of EGR-1 in human HT-1080 fibrosarcoma cells uses increased secretion of biologically active TGF-beta 1 in direct proportion (rPearson = 0.96) to the amount of EGR-1 expressed and addition of recombinant human TGF-beta 1 is strongly growth-suppressive for these cells. Addition of monoclonal anti-TGF-beta 1 antibodies to EGR-1-expressing HT-1080 cells completely reverses the growth inhibitory effects of EGR-1. Reporter constructs bearing the EGR-1 binding segment of the TGF-beta 1 promoter was activated 4- to 6-fold relative to a control reporter in either HT-1080 cells that stably expressed or parental cells cotransfected with an EGR-1 expression vector. Expression of delta EGR-1, a mutant that cannot interact with the corepressors, nerve growth factor-activated factor binding proteins NAB1 and NAB2, due to deletion of the repressor domain, exhibited enhanced transactivation of 2- to 3.5-fold over that of wild-type EGR-1 showing that the reporter construct reflected the appropriate in vivo regulatory context. The EGR-1-stimulated transactivation was inhibited by expression of the Wilms tumor suppressor, a known specific DNA-binding competitor. These results indicate that EGR-1 suppresses growth of human HT-1080 fibrosarcoma cells by induction of TGF-beta 1.

Suppression of growth and transformation and induction of apoptosis by EGR-1.

Transcription Factor EGR-1 Suppresses the Growth and Transformation of Human HT-1080 Fibrosarcoma Cells by Induction of Transforming Growth Factor Beta 1.

Induction of IGF-1R expression by EGR-1 facilitates the growth of prostate cancer cells.

Early Growth Response-1 Suppresses Human Fibrosarcoma Cell Invasion and Angiogenesis.

Egr-1 suppresses breast cancer cells proliferation by arresting cell cycle progression via down-regulating CyclinDs.

Abstract LB-75: Glucocorticoid Receptor Activation Inhibits P53-Induced Apoptosis of MCF10A Myc Cells Via Induction of Protein Kinase C Epsilon

The Role of the Transcription Factor EGR1 in Cancer

EB1 acts as an oncogene via activating beta-catenin/TCF pathway to promote cellular growth and inhibit apoptosis

EGR1 Decreases the Malignancy of Human Non-Small Cell Lung Carcinoma by Regulating KRT18 Expression.

EGR1 Promotes Proliferation in Prostatic Hyperplasia Epithelial BPH-1 Cells

Early Growth Response 1 Strengthens Pol-III-Directed Transcription and Transformed Cell Proliferation by Controlling PTEN/AKT Signalling Activity

Early growth response 2 (Egr2) plays opposing roles in committing C3H10T1/2 stem cells to adipocytes and smooth muscle-like cells.

Early Growth Response-1 is a New Substrate of the GSK3β-FBXW7 Axis.

Coactivating Factors P300 and CBP Are Transcriptionally Crossregulated by Egr1 in Prostate Cells, Leading to Divergent Responses

P53 And P73 Transactivate The Proapoptotic Early Growth Response Factor Egr2, And Its Expression Is Induced By Small Molecules That Restore P53 Signaling In Tumor Cells

E2f1 Induces Tumor Cell Survival Via Nuclear Factor-Kappa B-Dependent Induction of Egr1 Transcription in Prostate Cancer Cells

Drm/Gremlin transcriptionally activates p21Cip1 via a novel mechanism and inhibits neoplastic transformation

EGR1 Interacts with DNMT3L to Inhibit the Transcription of Mir‐195 and Plays an Anti‐apoptotic Role in the Development of Gastric Cancer

Egr-1 Participates in Abnormally High Gdnf Gene Transcription Mediated by Histone Hyperacetylation in Glioma Cells

Concurrent Down-Regulation of Egr-1 and Gelsolin in the Majority of Human Breast Cancer Cells.

Inhibition of EGR1 Inhibits Glioma Proliferation by Targeting CCND1 Promoter